Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK.
School of Sport & Exercise Sciences, Liverpool John Moores University, Liverpool, UK.
J Inherit Metab Dis. 2024 Jul;47(4):664-673. doi: 10.1002/jimd.12728. Epub 2024 Mar 15.
Altered activity of specific enzymes in phenylalanine-tyrosine (phe-tyr) metabolism results in incomplete breakdown of various metabolite substrates in this pathway. Increased biofluid concentration and tissue accumulation of the phe-tyr pathway metabolite homogentisic acid (HGA) is central to pathophysiology in the inherited disorder alkaptonuria (AKU). Accumulation of metabolites upstream of HGA, including tyrosine, occurs in patients on nitisinone, a licenced drug for AKU and hereditary tyrosinaemia type 1, which inhibits the enzyme responsible for HGA production. The aim of this study was to investigate the phe-tyr metabolite content of key biofluids and tissues in AKU mice on and off nitisinone to gain new insights into the biodistribution of metabolites in these altered metabolic states. The data show for the first time that HGA is present in bile in AKU (mean [±SD] = 1003[±410] μmol/L; nitisinone-treated AKU mean [±SD] = 45[±23] μmol/L). Biliary tyrosine, 3(4-hydroxyphenyl)pyruvic acid (HPPA) and 3(4-hydroxyphenyl)lactic acid (HPLA) are also increased on nitisinone. Urine was confirmed as the dominant elimination route of HGA in untreated AKU, but with indication of biliary excretion. These data provide new insights into pathways of phe-tyr metabolite biodistribution and metabolism, showing for the first time that hepatobiliary excretion contributes to the total pool of metabolites in this pathway. Our data suggest that biliary elimination of organic acids and other metabolites may play an underappreciated role in disorders of metabolism. We propose that our finding of approximately 3.8 times greater urinary HGA excretion in AKU mice compared with patients is one reason for the lack of extensive tissue ochronosis in the AKU mouse model.
苯丙氨酸-酪氨酸(phe-tyr)代谢中特定酶活性的改变导致该途径中各种代谢物底物的不完全分解。生物流体中phe-tyr 代谢物同型胱氨酸(HGA)浓度的增加和组织积累是遗传性疾病尿黑酸尿症(AKU)发病机制的核心。在 nitisinone(一种用于 AKU 和遗传性酪氨酸血症 1 型的许可药物)治疗的患者中,HGA 上游的代谢物,包括酪氨酸,也会积累,nitisinone 抑制了负责 HGA 产生的酶。本研究旨在研究 AKU 小鼠在 nitisinone 治疗和未治疗时关键生物体液和组织中的 phe-tyr 代谢物含量,以深入了解这些代谢改变状态下代谢物的分布情况。数据首次表明,HGA 存在于 AKU 的胆汁中(平均值[±标准差] = 1003[±410] μmol/L;nitisinone 治疗的 AKU 平均值[±标准差] = 45[±23] μmol/L)。胆汁中的酪氨酸、3(4-羟苯基)丙酮酸(HPPA)和 3(4-羟苯基)乳酸(HPLA)也在 nitisinone 治疗时增加。未经治疗的 AKU 中,尿液是 HGA 的主要排泄途径,但有胆汁排泄的迹象。这些数据提供了 phe-tyr 代谢物分布和代谢途径的新见解,首次表明肝胆排泄有助于该途径中代谢物的总池。我们的数据表明,有机酸酸和其他代谢物的胆汁排泄可能在代谢紊乱中发挥了被低估的作用。我们提出,我们在 AKU 小鼠中发现的 HGA 排泄量比患者高约 3.8 倍,这是 AKU 小鼠模型中组织褐黄病不广泛的原因之一。